Nateglinide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nateglinide
Nateglinide.svg
Systematic (IUPAC) name
3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
Clinical data
Trade names Starlix
AHFS/Drugs.com monograph
MedlinePlus a699057
Licence data EMA:Link, US FDA:link
Legal status POM (UK) -only (US)
Routes Oral
Pharmacokinetic data
Protein binding 98%
Half-life 1.5 hours
Identifiers
CAS number 105816-04-4 YesY
ATC code A10BX03
PubChem CID 60026
DrugBank DB00731
ChemSpider 10482084 YesY
UNII 41X3PWK4O2 YesY
KEGG D01111 N
ChEBI CHEBI:31897 N
ChEMBL CHEMBL286559 N
Chemical data
Formula C19H27NO3 
Mol. mass 317.423 g/mol
 N (what is this?)  (verify)

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology[edit]

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Contraindications[edit]

Nateglinide is contraindicated in patients who:

Dosage[edit]

Nateglinide is delivered in 60mg & 120mg tablet form.

External links[edit]